Bussiness1 week ago
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the...
